The Treponema denticola FhbB protein contributes to immune evasion by binding factor H (FH). Cleavage of FH by the T. denticola protease, dentilisin, may contribute to the local immune dysregulation that is characteristic of periodontal disease (PD). Although three FhbB phyletic types have been defined (FhbB1, FhbB2, and FhbB3), the in vivo expression patterns and antigenic heterogeneity of FhbB have not been assessed. Here, we demonstrate that FhbB is a dominant early antigen that elicits FhbB type-specific antibody (Ab) responses. Using the murine skin abscess model, we demonstrate that the presence or absence of FhbB or dentilisin significantly influences Ab responses to infection and skin abscess formation. Competitive binding analyses revealed that ␣-FhbB Ab can compete with FH for binding to T. denticola and block dentilisin-mediated FH cleavage. Lastly, we demonstrate that dentilisin cleavage sites reside within critical functional domains of FH, including the complement regulatory domain formed by CCPs 1 to 4. Analysis of the FH cleavage products revealed that they lack cofactor activity. The data presented here provide insight into the in vivo significance of dentilisin, FhbB and its antigenic diversity, and the potential impact of FH cleavage on the regulation of complement activation. P eriodontal disease (PD) of infectious etiology is a significant human and veterinary health concern. PD is a chronic inflammatory disease that degrades tissue and reabsorbs bone that surrounds and supports teeth, leading to endentulism (1). PD results from a dysbiosis of the polymicrobial community of the subgingival crevice. The transition of the bacterial population from predominantly Gram-positive organisms to destructive anaerobic spirochetes and Gram-negative organisms (2-4) is accompanied by local dysregulation of immunoregulatory mechanisms (5-8). Specific periopathogens, including Treponema denticola and Porphyromonas gingivalis, are thought to play leading roles in this process (8) (9) (10) . This study is focused on T. denticola, an anaerobic, proteolytic (tissue degrading) spirochete of humans that is a dominant periopathogen and member of the "red microbial complex" (4, 11). T. denticola and other oral treponemes are also key players in root canal and endodontic infections (12, 13).
P
eriodontal disease (PD) of infectious etiology is a significant human and veterinary health concern. PD is a chronic inflammatory disease that degrades tissue and reabsorbs bone that surrounds and supports teeth, leading to endentulism (1) . PD results from a dysbiosis of the polymicrobial community of the subgingival crevice. The transition of the bacterial population from predominantly Gram-positive organisms to destructive anaerobic spirochetes and Gram-negative organisms (2-4) is accompanied by local dysregulation of immunoregulatory mechanisms (5) (6) (7) (8) . Specific periopathogens, including Treponema denticola and Porphyromonas gingivalis, are thought to play leading roles in this process (8) (9) (10) . This study is focused on T. denticola, an anaerobic, proteolytic (tissue degrading) spirochete of humans that is a dominant periopathogen and member of the "red microbial complex" (4, 11) . T. denticola and other oral treponemes are also key players in root canal and endodontic infections (12, 13) .
Periopathogens thrive in the subgingival crevice, an anatomical niche bathed in gingival crevicular fluid (GCF). GCF is derived from serum and local tissue exudate (14) and is rich in immune effectors, including activated complement, C-reactive protein, opsonins (C3b and iC3b), anaphylatoxins, and proinflammatory cytokines (reviewed in references 1 and 15). T. denticola evades complement mediated destruction by binding factor H (FH), a negative regulator of the complement system (9, (16) (17) (18) . FH, an abundant 150-kDa serum glycoprotein (ϳ300 g ml of serum Ϫ1 ) (19, 20) , consists of 20 imperfect repeat domains (CCPs) of 50 to 60 amino acids each that comprise different functional domains (21) (22) (23) (24) (25) .
The FH binding protein of T. denticola, FhbB, is a surfaceexposed 11.4-kDa lipoprotein (16, 26) . The molecular structure of FhbB has been determined, and the kinetics and molecular basis of its interaction with FH have been well characterized (5, 17, 18, 27) .
FhbB proteins are divided into three major phyletic clusters or phyletic types designated FhbB1, FhbB2, and FhbB3 (17, 18) . In spite of significant sequence variation within the FH binding interface of different FhbB types, all bind FH with similar binding kinetics. Although FH binding to T. denticola is essential for complement evasion, it is something of a paradox that surface-bound FH is cleaved by the T. denticola protease, dentilisin (10) . It has been speculated that FH depletion alters the physiochemical and immunological environment of the subgingival crevice resulting in conditions that enhance the growth of periopathogens and promote disease progression.
We demonstrate here that antibody (Ab) responses to FhbB proteins are FhbB type specific and that FhbB is a dominant early antigen. Infection of mice using a T. denticola-skin abscess model (28) revealed that the presence or absence of FhbB in the cell influences Ab responses to T. denticola proteins. Furthermore, using this model, both dentilisin and FhbB were found to play a significant role in abscess formation. FH and Ab competitive binding analyses revealed that the binding sites for ␣-FhbB Ab and FH overlap. As expected from the competitive binding data, Ab bound to FhbB blocked degradation of FH by dentilisin (in a type-specific manner). Lastly, we demonstrate that dentilisin cleaves multiple sites within the CCP1 to CCP4 domain of FH, a binding site for C3b (29) , and inactivates cofactor activity. The data presented here demonstrate the in vivo biological significance of FhbB and dentilisin and provide a comprehensive assessment of the specificity of Ab responses to this important virulence factor.
MATERIALS AND METHODS
Bacterial strains, generation of recombinant proteins, and ␣-FhbB antisera. All T. denticola strains used in this study were grown in new oral spirochete medium supplemented with 4 mg of thiamine pyrophosphate liter Ϫ1 under anaerobic conditions (5% H 2 , 5% CO 2 , 90% N 2 ) (17). T. denticola 35405⌬fhbB is an fhbB deletion mutant (9), and T. denticola 35405-CCE is a dentilisin insertional inactivation mutant (30) . T. denticola strains 35405, MS25, GM1, N17A1, and 33520 produce FhbB1 proteins. T. denticola strains SP55, SP54, SP50, SP49, SP48, and SP72 produce FhbB2 proteins, and strains SP64, 35404, 33521, CF171, and CF170 produce FhbB3 proteins (17) . All recombinant proteins were generated with N-terminal His tag fusions and purified using standard, previously described approaches (17) . The complement regulatory domain of FH, which consists of complement control protein modules 1 through 4 (CCP1-4), was generated and refolded as described previously (17) . The FhbB protein nomenclature used here is as follows: FhbB (FH binding protein B) is followed by a number designation to indicate phyletic type (FhbB1, FhbB2, or FhbB3) and a subscript to indicate the isolate of origin. Antisera were generated against FhbB1 35405 , Fhb2 SP50 , Fhb2 SP64 , FhbB3 33521 , and FhbB3 35404 in female Sprague-Dawley rats (two rats per antigen). Rats were anesthetized with a ketamine-xylazine-acepromazine cocktail, injected intraperitoneally with 40 g of protein (complete Freund adjuvant; Sigma-Aldrich), and boosted at weeks 3 and 5 (40 g protein in Freund incomplete adjuvant). At week 7, the rats were euthanized, blood was collected by cardiac puncture, and the sera were harvested. All animal procedures were conducted according to the Guide for the Care and Use of Laboratory Animals (eighth edition) and in accordance with protocols approved by the institutional animal care and use committees of Virginia Commonwealth University Medical Center, the University of Connecticut Health Center, and the State University of New York at Buffalo.
T. denticola mouse abscess model. Four-week-old BALB/c mice (Jackson Laboratories, Bar Harbor, ME) were infected with wild-type (wt) strain 35405, strain 35405⌬fhbB, or strain 35405-CCE (six mice per bacterial strain) by subcutaneous inoculation of a bacterial suspension (100 l, ϳ10 9 cells) on their posterior dorsolateral surfaces. At 10 or 20 days postinjection, groups of mice were euthanized by CO 2 asphyxiation, blood was collected, and the serum was harvested. The area surrounding the injection on the posterior dorsolateral surface was excised, and the abscess size was measured as previously described (31, 32) .
Immunoblot procedures and FH affinity ligand-binding immunoblot (ALBI) assays. T. denticola cells (optical density at 600 nm [OD 600 ] of 1) were harvested by centrifugation, washed, suspended in standard 1ϫ SDS-PAGE solubilizing solution (300 l), sonicated, loaded (5 l), subjected to SDS-PAGE (18% Criterion gels; Bio-Rad), and transferred to polyvinylidene difluoride (PVDF) membranes by electroblotting. The following dilutions of antisera in PBSTM (PBS with 0.02% Tween 20 and 5% nonfat dry milk) were used: rat ␣-FhbB1, ␣-FhbB2, or ␣-FhbB3 antiserum (1:10,000 dilution), rabbit ␣-T. denticola FlaA antiserum (1:10,000 dilution), mouse ␣-T. denticola 35405 infection serum (1:5,000), mouse ␣-T. denticola 35405⌬fhbB infection serum (1:5,000), mouse ␣-T. denticola 35405-CCE infection serum (1:5,000), and goat ␣-human C3 antiserum (1:5,000; Complement Tech). Species appropriate horseradish peroxidase (HRP)-conjugated ␣-IgG secondary antibodies (Pierce) were used at dilutions of 1:40,000. Detection was accomplished using chemiluminescence with Clarity Western ECL substrate (Bio-Rad), as instructed by the supplier. The ALBI assays were conducted by incubating immunoblots in PBSTM with purified human FH (10 ng l Ϫ1 ) overnight at 4°C. The membranes were washed and screened with goat anti-human FH (1:5,000 dilution; Complement Tech), and Ab binding was detected as described above.
FH-Ab competitive binding ELISAs. To determine whether FH and ␣-FhbB Ab binding sites on FhbB overlap and to determine whether potential competition is FhbB type specific, competitive enzyme-linked immunosorbent assays (ELISAs) were performed. Recombinant FhbB proteins were immobilized in 96-well ELISA plates in triplicate (1 g per well; overnight; 4°C; 100 mM NaHCO [pH 9.6]), nonspecific binding blocked with PBSTM (1 h) and dilutions of rat ␣-FhbB type-specific antisera added (1:150 to 1:4,050 in PBSTM; 1 h). Plate wells were washed 3 times with PBST. All wash steps in all ELISAs were conducted in an identical manner. Complement certified normal human serum (NHS; 10% in PBST; Innovative Research) served as the FH source and was added to all wells for 1 h. After washing, goat ␣-human FH was added (1:1,000 in PBSTM; 1 h; Complement Tech), the plates were washed, and Ab binding was detected with HRP-conjugated rabbit ␣-goat IgG (1:20,000 in PB-STM; 1 h; Calbiochem) with ABTS [2,2=azinobis(3-ethylbenzthiazolinesulfonic acid)] serving as the substrate. The absorbance was measured at 405 nm (Biotek). The data presented are representative of three independent experiments. As a negative control, wells were coated with PBSTM alone with no ␣-FhbB antiserum added. In addition, r-FhbA from the Borrelia hermsii DAH strain, which is not antigenically related to FhbB served as a negative control (33) .
Analysis of the ability of ␣-FhbB Ab to inhibit FH cleavage by dentilisin. T. denticola 35405 and 35405-CCE (negative control) were cultivated, harvested by centrifugation and washed with PBS, and 0.1 OD 600 unit of cells was suspended in 50 l of PBS containing purified human FH (40 g l Ϫ1 ; Complement Tech). ␣-FhbB1 35405 antiserum was added at final concentrations of 0, 0.5, 1.0, and 10% (37°C; shaking; 0 or 60 min), and the samples were prepared for SDS-PAGE and immunoblotting.
Mapping of a dentilisin cleavage site within CCP1-4 and assessment of the cofactor activity of dentilisin generated FH cleavage products. To determine whether dentilisin cleaves FH within CCP1-4, purified human FH and recombinant His-tagged CCP1-4 (20 g ml Ϫ1 ) generated in Escherichia coli (5) were incubated with T. denticola 35405 or 35405-CCE (0 or 120 min; 37°C). In a second set of experiments, the cleavage of CCP1-4 was assessed over time. The samples from each time point were prepared for SDS-PAGE, transferred to membranes, and screened with ␣-human FH antiserum as described above. The 35405-CCE strain, which lacks dentilisin activity, served as a negative control. To determine whether dentilisin-generated FH cleavage products retain complement regulatory activity, purified human FH was incubated with T. denticola 35405 and 35405-CCE cells as described above. After incubation, cells and cellular debris were removed by centrifugation (5,000 ϫ g, 5 min, room temperature), supernatants were collected and filtered (0.22-m-pore-size PVDF centrifugal filters; Millipore), and aliquots were incubated with human C3b (100 ng; Complement Tech) and or human factor I (FI; 1 g; Complement Tech) in phosphate-buffered saline (PBS; 20-l final reaction volume; 60 min; 37°C). Solution controls (no cells added) consisted of FH and or FI incubated with C3b in PBS, as detailed above. The samples were prepared for immunoblot analyses and screened with ␣-human C3 Ab, and Ab binding was detected as above.
RESULTS

FhbB proteins elicit type-specific Ab responses.
To determine whether recombinant FhbB1, FhbB2, and FhbB3 proteins elicit type/ variant specific Ab responses, identical immunoblots of a panel of T. denticola isolates (cell lysates) that produce known FhbBtype proteins were screened with ␣-FhbB1 35405 , ␣-FhbB2 SP50 , ␣-FhbB3 SP64 , ␣-FhbB3 35404 , and ␣-FhbB3 33521 antisera (Fig. 1) . No cross-reactivity of the antisera was observed with proteins of heterologous FhbB types. The FhbB3 proteins, FhbB3 35404 , and FhbB3 SP64 , are antigenically distinct from each other, as well as from other FhbB3 variants. The Ab response to FhbB proved to be type specific during infection as well. Serum from mice that were infected with strain 35405 using the murine skin abscess model reacted only with FhbB1 proteins, with no cross-reactivity with FhbB2 or FhbB3 proteins.
To further investigate the influence of FhbB and dentilisin on Ab responses and abscess formation, mice were infected with strains 35405 (FhbB ϩ , dentilisin ϩ ), 35405⌬fhbB (FhbB Ϫ , dentilisin ϩ ), and 35405-CCE (FhbB ϩ , dentilisin Ϫ ), and serum samples were harvested at 10 or 20 days postinfection. Immunoblots of 35405, 35405⌬fhbB, and 35405-CCE cell lysates derived from spirochetes grown under standard conditions were screened with serum from each mouse (Fig. 2) . Strikingly, the most dominant in vitro-produced protein recognized by Ab in sera from mice infected with 35405 and 35405-CCE, but not from mice infected with 35405⌬fhbB, was FhbB. The identity of this protein as FhbB was confirmed based on multiple observations. A protein consistent in size with FhbB was not detected in the 35405⌬fhbB strain by serum from infected mice or with ␣-FhbB antisera, while a protein of the appropriate size was detected in strains 35405 and 35405-CCE that reacted with ␣-FhbB1 antisera and bound FH. It is noteworthy that the IgG response to T. denticola 35405⌬fhbB proteins in infected mice differed significantly from that seen in mice that were infected with FhbB producing strains. Specifically, stronger reactivity on immunoblots was observed with several higher-molecular-weight proteins when screened with the ␣-35405⌬fhbB serum. It is noteworthy that, as assessed by immunoblotting, significant IgM responses were not detected in mice infected with any of the strains tested (data not shown).
The presence or absence of FhbB or dentilisin was also found to influence abscess formation. A reduction in abscess size was consistently observed in mice infected with 35405⌬fhbB. However, the reduction in abscess size at day 10 postinoculation (the only time point tested) was just outside the range of statistical significance (P ϭ 0.0626). Abscess size in mice infected with the CCE strain was markedly reduced and of clear statistical significance (P ϭ 0.0004).
␣-FhbB Ab competes with FH for binding to FhbB proteins. The specificity of the Ab response suggests that the immunodominant epitopes of FhbB reside within its variable domain which also serves as its FH binding interface (5, 18) . To determine whether FH and ␣-FhbB Ab compete for binding and to determine whether binding competition occurs in an FhbB-type-specific manner, competitive binding ELISAs were conducted. Immobilized recombinant FhbB proteins were incubated with increasing dilutions of type-specific ␣-FhbB antisera, with NHS serving as the FH source. ␣-FhbB1 35405 inhibited FH binding to FhbB1 35405 but not to FhbB2 or FhbB3 proteins in a dose-dependent manner (Fig. 3) . Similarly, ␣-FhbB2 SP50 , ␣-FhbB3 33521 , and ␣-FhbB3 35404 selectively inhibited FH binding to the homologous protein. Binding of FH to FhbB SP64 was not inhibited by any of the antisera tested, a finding consistent with the antigenic uniqueness of this variant. As expected, ␣-FhbB antisera had no effect on FH binding to the antigenically unrelated B. hermsii FhbA protein (33) . The data indicate that ␣-FhbB Ab and FH bind to the same face of FhbB and that Ab effectively competes with FH for binding in a type-specific manner.
␣-FhbB Ab blocks or attenuates the dentilisin-mediated degradation of FH. Since ␣-FhbB Ab outcompetes FH for binding to FhbB, we speculated that ␣-FhbB Ab should also inhibit FH degradation by T. denticola. To test this, 35405 and 35405-CCE cells were incubated with FH and dilutions of ␣-FhbB1 35405 antiserum. FH degradation was assessed through immunoblotting as detailed above using ␣-FH antiserum.
␣-FhbB1 35405 antiserum inhibited FH degradation in a concentration-dependent manner (Fig. 4A) . To determine whether Ab generated against other FhbB types inhibits FH degradation by T. denticola 35405 (an FhbB1 strain), cells were incubated with FH and antisera raised against heterologous FhbB proteins (Fig.  4B) . Degradation of FH by T. denticola 35405 was blocked by ␣-FhbB1 35405 Ab but not by ␣-FhbB2 SP50 , ␣-FhbB3 33521 , or ␣-FhbB3 35404 Ab. These data further confirm the specificity of the Ab response to FhbB and raise the possibility that ␣-FhbB Ab could be used therapeutically to block FH cleavage.
Dentilisin cleaves FH within the CCP1-4 domain and inactivates cofactor activity. CCP1-4 is a critical FH domain that regulates cofactor and decay accelerating activity (29, 34) . If dentilisin cleaves within CCP1-4, the resulting cleavage products would be expected to lack cofactor activity. Using the human FH sequence (CAA68704.1), the number of Pro-Phe (PF) motifs was determined to be 1. This site maps to amino acid residues 92 and 93 within CCP2. Since dentilisin is classified as a chymotrypsin-like protease, we also determined the number of potential chymotrypsin cleavage sites using the Expasy Peptide Cutter Tool since these sites could also be cleaved by dentilisin. Only sites with a predicted cleavage probability score of Ն96.6% were considered. Twentytwo high probability chymotrypsin cleavage sites were identified, eight of which reside within CCP1-4 (Fig. 5A) . The number of potential cleavage sites is consistent with, and provides a plausible explanation for, the complete degradation of FH by T. denticola FhbB ϩ /dentilisin ϩ strains (18) . To determine whether cleavage of CCP1-4 occurs at the potential dentilisin Pro-Phe cleavage motif and or other discrete sites, CCP1-4 was incubated with each strain, and aliquots of the mixture were removed at different time points (0 to 60 min), immediately mixed with SDS solubilizing solution and boiled to ensure the inactivation of proteases. Analysis of the samples by immunoblotting using ␣-FH Ab demonstrated a distinct cleavage fragment within the first 2 min of incubation (Fig.  5B) . After 2 min, this fragment was fully degraded and no distinct cleavage products were evident after 5 min. Full-length CCP1-4 was fully degraded by 30 min. CCP1-4 was not degraded when incubated with the dentilisin deficient strain, 35405-CCE. The interpretation and implications of these data are discussed in detail below.
To determine whether the FH fragments generated by dentilisin cleavage retain cofactor activity, filtered supernatants from T. denticola 35405 and 35405-CCE cells that had been incubated with FH were mixed with FI and or C3b. The samples were then fractionated by SDS-PAGE, and immunoblots were screened with ␣-C3b antiserum. The 35405 supernatant lacked FH cofactor activity, whereas the supernatant from the 35405-CCE strain had readily detectable cofactor activity as evidenced by the detection of C3dg (Fig. 5C ). Consistent with an earlier report (16) , a smaller C3b derived cleavage fragment was observed when 35405 supernatant was incubated with C3b in the absence of FH and FI. The fact that this fragment is not observed when C3b is incubated with the 35405-CCE strain indicates that it is generated through a dentilisin-dependent but an FI-and FH-independent mechanism. Solution controls (supernatant free) for these analyses yielded the expected results, i.e., C3b was only cleaved when both FH and FI were added. It can be concluded that dentilisin completely inactivates the ability of FH to serve as a cofactor in the FI-mediated cleavage of C3b.
DISCUSSION
The binding of FH to FhbB and its subsequent cleavage by dentilisin have been postulated to play a central role in the pathogenesis of T. denticola (9, 10, 16, 35) . As the T. denticola population expands with the development of PD, the rate of FH cleavage in GCF may exceed its rate of replenishment, resulting in localized immune dysregulation (5, 35) . We have hypothesized that T. denticola mediated complement dysregulation could be blocked using an FhbB-based vaccine or a therapeutic ␣-FhbB Ab cocktail. Defining the antigenic diversity of FhbB is essential to move forward with the development of novel preventive or therapeutic approaches for PD. In an earlier analysis of FhbB protein sequences, three major distinct phyletic types were defined (5, 17) . Here, we demonstrate that IgG responses to FhbB are type specific and thus likely target the negatively charged variable face of the protein, which has been demonstrated to be the FH interaction domain. Consistent with this, ␣-FhbB Ab blocks FH binding and cleavage but does so in a type-specific fashion. Type-specific Ab responses to FhbB were also demonstrated in vivo using the murine abscess model. Furthermore, this model revealed that maximal abscess formation is dependent on both FhbB and dentilisin. Lastly, we show that dentilisin cleaves within CCP1-4, a critical functional domain of FH, and thereby inactivates cofactor activity.
The specificity of Ab responses to FhbB proteins was demonstrated through immunoblot analyses. ␣-FhbB1 antisera detected only FhbB1 proteins and ␣-FhbB2 antisera detected only FhbB2 proteins (Fig. 1) . Proteins of the FhbB3 phyletic cluster displayed greater antigenic diversity with some variants being antigenically distinct. In no case did ␣-FhbB antisera cross-react with a heterologous FhbB type protein. FhbB type-specific Ab responses were also observed in vivo. Mice infected by subcutaneous injection with the FhbB1-producing T. denticola 35405 strain developed a strong IgG response that was FhbB1 type specific. In light of the relatively high amino acid sequence identity values among FhbB proteins and the surface exposure of conserved domains (as demonstrated by its atomic structure) (5, 27) , the type specificity of the Ab response was surprising. Many spirochetal FH binding proteins bind additional host-derived serum proteins (36, 37) . It is possible that the nonantigenic, conserved regions of FhbB bind serum-derived proteins that prevent this region from eliciting or being bound by Ab.
The potential importance of FhbB in vivo was evident from immunoblot analyses, which revealed that FhbB is a dominant antigen in mice with T. denticola-induced abscesses (Fig. 2) . Serum harvested 10 or 20 days after inoculation of mice with strain 35405 or strain 35405-CCE, but not strain 35405⌬fhbB, reacted strongly with FhbB with only minimal detection of other T. denticola proteins. T. denticola has been reported to produce a relatively small repertoire of surface antigens during infection, and the data presented here are consistent with earlier observations (38, 39) . Interestingly, in studies by Abiko et al. the most dominant protein detected through immunoblot analyses using serum from infected mice was an ϳ11-kDa protein consistent in size with FhbB (38, 39) . However, Abiko et al. did not discuss the 11-kDa protein and instead focused on higher-molecular-weight antigens, including OppA (75 kDa), Msp (52 kDa), and TmpC (37 kDa). It is noteworthy that the set of proteins recognized by sera from mice infected with the 35405⌬fhbB strain differed both qualitatively and quantitatively from that observed when cell lysates were screened with sera from mice infected with strain 35405 or 35405-CCE. The dominant proteins detected by IgG in mice infected with 35405⌬fhbB were ϳ75 and 50 kDa in size, an observation consistent with OppA and Msp, respectively. As expected, since fhbB is deleted in this strain, there was no detection of the 11-kDa protein described above. The differences in the antigen profiles may reflect the need for T. denticola to upregulate other membrane proteins in the absence of FhbB to maintain cell integrity.
The FhbB type-specific Ab responses that develop against FhbB strongly suggest that the immunodominant epitopes reside with the variable domains of FhbB proteins which also serve as the FH interaction site (5) . Consistent with this, competitive binding studies revealed that FH and ␣-FhbB Ab compete for binding to FhbB (Fig. 3) . As demonstrated in the present study, Ab elicited against recombinant FhbB proteins can compete with FH for binding to FhbB and can block FH cleavage by T. denticola. ␣-FhbB Ab effectively blocks FH binding and therefore also prevents its cleavage by dentilisin. The blocking ability of Ab occurs in a type-specific manner. Hence, a potential chimeric FhbB-based vaccine or therapeutic ␣-FhbB Ab cocktail that is intended to restore complement regulation by inhibiting T. denticola growth will require the inclusion of each major FhbB type.
Although it has been generally assumed the dentilisin plays a role in tissue degradation and abscess formation, it has not to our knowledge been directly assessed. Using gene deletion/inactivation mutants of FhbB and dentilisin in the murine abscess model, we demonstrate here that both proteins contribute to maximal abscess formation. A significant reduction in abscess size was observed in mice inoculated with the dentilisin-deficient CCE strain relative to the parental wild-type strain, 35405 (P ϭ 0.0004). A reduced abscess size was also noted in mice inoculated with 35405⌬fhbB, but the difference, while consistent, was noteworthy but just below the significance threshold cutoff (P ϭ 0.0626). It is clear that both dentilisin and FhbB are required for maximal abscess formation. The underlying mechanisms that drive the destructive tissue degradation that occurs with PD are most likely driven by both the pathogen and the host immune system. There is likely direct degradation by dentilisin and potentially additional destruction induced by local immune dysregulation due to FH cleavage and C3b accumulation. Future studies will define the molecular basis of abscess formation by T. denticola.
We have proposed that FH cleavage by dentilisin results in loss of FH cofactor activity. For this to occur, the critical CCP1-4 domain would need to be rendered nonfunctional. The locations of dentilisin cleavage sites within FH have not been previously deter-mined. Earlier studies using peptide-p-nitroanilide substrates indicated that Pro-Phe motifs are the primary cleavage motif (40) . However, FH, which is completely degraded by dentilisin, has only a single Pro-Phe motif at amino acid positions 92 and 93. Importantly, this site resides within CCP2. To determine whether this site is a target for dentilisin, we monitored cleavage of recombinant CCP1-4 over time. We reasoned that at early time points it might be possible to identify specific fragments that are indicative of the initial cleavage sites of dentilisin prior to the complete degradation of FH. A discrete CCP1-4-derived cleavage product of 19 kDa was detected within seconds of the exposure of recombinant CCP1-4 (26 kDa) to the dentilisin-positive 35405 strain (but not dentilisin-negative strains) (Fig. 5) . The detection intensity of this fragment by ␣-FH antiserum increased to ϳ2 min postexposure but then rapidly decreased. Consistent with the appearance of the 19-kDa fragment, cleavage at position 92 or 93 would be expected to yield fragments of 19 and 7 kDa. No detectable discrete cleavage fragments of any specific size were observed after 5 min of incubation. Consistent with the cleavage of FH within CCP1-4 detailed above, cofactor activity was not detected in the supernatant collected from T. denticola 35405 cells that were incubated with FH. It can be concluded that dentilisin cleaves FH within critical functional domains and that this activity in vivo could affect FH-associated regulation of the complement system. Importantly, since FH and CCP1-4 become completely degraded over time, there are clearly other cleavage sites for dentilisin in addition to the Pro-Phe motif. Since dentilisin is classified as a chymotrypsin-like protease, PEPTIDE cutter was used to identify potential chymotrypsin cleavage sites with predictive probabilities of Ն96.6%. Twenty-two such sites were identified with many residing within CCPs that are binding sites for C3b, C3c, C3d, monomeric C-reactive protein, and glycosaminoglycans (heparin) (Fig. 5A) . It remains to be determined whether dentilisin cleaves at these sites or, alternatively, whether it possesses exoprotease activity.
The cleavage of FH by T. denticola, a protein required for evasion of complement (at least in vitro in human serum), is somewhat of a paradox since cleavage would counter an important immune evasion mechanism of T. denticola (reviewed in reference 35) . McDowell et al. demonstrated that the 35405⌬fhbB strain is highly sensitive to complement-mediated killing, whereas the parental 35405 strain is not (9) . It is our hypothesis that FH-mediated immune evasion is essential for T. denticola's survival in the healthy subgingival crevice prior to the development of a welldeveloped biofilm. In the "healthy state," the abundance of T. denticola is low and thus the rate of FH degradation would not exceed its rate of replenishment. However, as the population expands, the rate of cleavage will exceed its rate of replenishment from serum. Depletion of FH would result in local immune dysregulation and promote the growth of T. denticola and other periopathogens and drive disease progression. A developed biofilm would also serve to physically protect the overall T. denticola population, and as a result, the need for FH-mediated immune evasion would be decreased. Targeting of T. denticola through vaccination with an FhbB-based vaccine or treatment with ␣-FhbB Abs could open the door to new preventive and therapeutic strategies for PD. The efficacy of an FhbB-based vaccine will be dependent on the ability of the vaccine construct to elicit Ab responses that can target all of the major FhbB phyletic types produced by T. denticola. One possible approach to consider is the development of a chimeric FhbB protein harboring the major FhbB types. The utility of chimeric proteins to elicit bactericidal Ab against diverse strains of the Lyme disease spirochetes has been demonstrated in several studies (41) (42) (43) . It may also be possible to exploit Ab directed at FhbB as a therapeutic tool for periodontal disease. A humanized monoclonal Ab cocktail could be delivered locally to diseased sites to inhibit the growth of T. denticola and reverse complement dysregulation. Studies are under way to explore these potentially new approaches for the prevention and or treatment of PD.
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